2141P Real world-data on neoadjuvant/definitive immunotherapy (IO) or chemo-immunotherapy (CT-IO) in patients (pts) with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) resectable or potentially resectable gastric/gastroesophageal junction (GEJ) carcinoma